Natera, Inc. (NASDAQ:NTRA) insider Jonathan Sheena sold 11,670 shares of the company's stock in a transaction on Wednesday, June 16th. The stock was sold at an average price of $101.12, for a total transaction of $1,180,070.40. Following the transaction, the insider now owns 462,465 shares in the company, valued at approximately $46,764,460.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Jonathan Sheena also recently made the following trade(s):
- On Thursday, June 10th, Jonathan Sheena sold 1,034 shares of Natera stock. The stock was sold at an average price of $102.60, for a total transaction of $106,088.40.
- On Tuesday, April 13th, Jonathan Sheena sold 3,213 shares of Natera stock. The stock was sold at an average price of $104.21, for a total transaction of $334,826.73.
- On Monday, March 29th, Jonathan Sheena sold 586 shares of Natera stock. The stock was sold at an average price of $83.95, for a total transaction of $49,194.70.
NASDAQ:NTRA traded up $6.42 during mid-day trading on Monday, hitting $109.30. 1,260,154 shares of the stock traded hands, compared to its average volume of 905,082. The firm's 50-day moving average is $99.97. The company has a debt-to-equity ratio of 0.75, a quick ratio of 4.60 and a current ratio of 4.74. The company has a market cap of $9.61 billion, a P/E ratio of -35.26 and a beta of 1.32. Natera, Inc. has a 12-month low of $43.20 and a 12-month high of $127.19.
Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, May 6th. The medical research company reported ($0.74) EPS for the quarter, beating analysts' consensus estimates of ($1.05) by $0.31. Natera had a negative net margin of 57.47% and a negative return on equity of 59.71%. The firm had revenue of $152.32 million during the quarter, compared to analyst estimates of $114.42 million. During the same period in the previous year, the business earned ($0.45) EPS. The business's revenue for the quarter was up 62.0% on a year-over-year basis. As a group, sell-side analysts predict that Natera, Inc. will post -3.93 EPS for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of NTRA. Rockefeller Capital Management L.P. bought a new stake in Natera during the first quarter valued at approximately $28,000. Tobam purchased a new position in Natera in the first quarter worth $38,000. Harvest Fund Management Co. Ltd purchased a new position in Natera in the fourth quarter worth $39,000. Benjamin F. Edwards & Company Inc. bought a new position in Natera in the first quarter valued at $49,000. Finally, AlphaMark Advisors LLC purchased a new stake in Natera during the first quarter valued at about $51,000. 96.09% of the stock is owned by institutional investors.
NTRA has been the topic of several research reports. Morgan Stanley lowered their price objective on shares of Natera from $140.00 to $135.00 and set an "overweight" rating on the stock in a report on Monday, May 10th. Truist Securities lowered their target price on shares of Natera from $143.00 to $129.00 and set a "buy" rating for the company in a report on Tuesday, May 25th. Zacks Investment Research upgraded shares of Natera from a "sell" rating to a "hold" rating in a report on Thursday, April 29th. Raymond James started coverage on shares of Natera in a report on Tuesday, June 15th. They issued a "market perform" rating for the company. Finally, Piper Sandler increased their price target on shares of Natera from $127.00 to $150.00 and gave the company an "overweight" rating in a research report on Friday, February 26th. Two analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company presently has a consensus rating of "Buy" and a consensus price target of $125.91.
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Further Reading: What is the Shanghai Stock Exchange Composite Index?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: What does a hold rating mean?7 Reddit Stocks That Have a Chance to Be Special
As a conservative investor, I have a grudging admiration for the small army of retail traders that are making their dreams come true. I’m talking, of course, about the group of day traders who have made a habit of finding low-priced stocks (particularly those with high short interest) and attempting to send them “to the moon.”
They are called meme stocks, casino stocks, or Reddit stocks (named for the website where some of these traders congregate). It all means the same thing. And as much as I say I admire the traders who have profited from these stocks, I do it from a safe distance.
Many of these stocks were penny stocks. And they were penny stocks for a reason. No amount of speculative rocket fuel is going to change that. But if you look at some of these stocks as objectively as possible, there may be hope.
And in this special presentation, we’re going to look at seven Reddit stocks that might just have a chance to have a life beyond this current mania phase.
View the "7 Reddit Stocks That Have a Chance to Be Special"